Advertisement

Multiple Myeloma and Plasmacytoma

  • Thomas T. Bui
  • Kavita Mishra
  • Mack RoachIII
Chapter

Abstract

Plasma cell tumors are monoclonal tumors of immunoglobulin-secreting cells, derived from B-cell lymphocytes. Incidence is low overall, ∼1–2% of U.S. cancers diagnosed yearly are plasma cell tumors. More than 90% of these are multiple myeloma (MM); ∼2–10% are solitary plasmacytoma (SP). MM incidence higher in blacks than whites (∼2:1). Median age at diagnosis 70 years. SP more common in men than women (4:1). Median age at diagnosis 50–55 years. Etiology is unknown, may involve occupational exposures, RT, solvents (Nau et al. 2008). 20% of patients are free of clinical symptoms at diagnosis. Osseous SP and MM may manifest as bone pain, neurologic symptoms, pathologic fracture, cord compression, anemia, hypercalcemia, renal insufficiency (Schechter et al. 2003).

Keywords

Multiple Myeloma Cord Compression Solitary Plasmacytoma Bone Marrow Plasma Cell Plasma Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCES

REFERENCES

  1. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 1999;85:2305-2314.PubMedCrossRefGoogle Scholar
  2. Catell D, Kogen Z, Donahue B, et al. Multiple myeloma of an extremity: must the entire bone be treated? Int J Radiat Oncol Biol Phys. 1998;40(1):117-119.PubMedCrossRefGoogle Scholar
  3. Creach CM, Foote RL, Netten-Wittich MA, et al. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys. 2009;73(3):789-794.PubMedCrossRefGoogle Scholar
  4. Hodgson DC, Mikhael J, Tsang RW. Plamsa cell myeloma and plasmacytomas. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.Google Scholar
  5. Hu K,Yahalom J. Radiotherapy in the Management of Plasma Cell Tumors. Oncology. 2000;14(1): 100-111.Google Scholar
  6. Intergroupe Francophone du Myelome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.CrossRefGoogle Scholar
  7. Kim P, Hicks RJ, Wirth A, et al. Impact of (18)F-Fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2008;74:740–746.PubMedCrossRefGoogle Scholar
  8. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347.PubMedCrossRefGoogle Scholar
  9. Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493.CrossRefGoogle Scholar
  10. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology v3.2010: Multiple Myeloma. Available at http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed on March 3, 2010.
  11. Nau K, Lewis W. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2008;78(7):853-859, 860.Google Scholar
  12. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210-217.PubMedCrossRefGoogle Scholar
  13. Schechter NR, Lewis VO. The Bone. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 8th ed. St. Louis: Mosby; 2003. pp. 857-883.Google Scholar
  14. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132(4):410-451.PubMedCrossRefGoogle Scholar

Further Readings

  1. Hu K,Yahalom J. Radiotherapy in the Management of Plasma Cell Tumors. Oncology. 2000;14(1): 100-111.Google Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Thomas T. Bui
    • 1
  • Kavita Mishra
    • 1
  • Mack RoachIII
    • 2
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations